Literature DB >> 9533728

Molecular evolution of rifampicin resistance in Streptococcus pneumoniae.

M Enright1, P Zawadski, P Pickerill, C G Dowson.   

Abstract

Rifampicin resistance has arisen in several different species of bacteria because of alterations to one or more regions in the target of the antibiotic, the beta-subunit of RNA polymerase encoded by rpoB. Nucleotide sequence analysis of a 270 bp fragment of rpoB from 16 clinical rifampicin-susceptible isolates of Streptococcus pneumoniae, 8 clinical rifampicin-resistant isolates, and 3 spontaneous rifampicin-resistant mutants, has revealed that, as with previously examined species, point mutations within the cluster I region of rpoB, at sites encoding Asp516 and HiS526, also confer resistance to rifampicin in this important human pathogen. Moreover, the residues within cluster I, that were altered within the rifampicin-resistant mutants of S. pneumoniae, were in the same position as those previously found to alter in resistant isolates of Escherichia coli and Mycobacterium tuberculosis. Sequence analysis of rpoB, both from these isolates of S. pneumoniae and from two strains of S. mitis, reveals that, among a number of clinical isolates, resistance to rifampicin in S. pneumoniae has arisen by point mutation. However, the nucleotide sequence of rpoB from one isolate examined suggests that interspecies gene transfer may also have played a role in the evolution of rifampicin-resistance in S. pneumoniae.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9533728     DOI: 10.1089/mdr.1998.4.65

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  18 in total

1.  RNA polymerase inhibitors with activity against rifampin-resistant mutants of Staphylococcus aureus.

Authors:  A O'Neill; B Oliva; C Storey; A Hoyle; C Fishwick; I Chopra
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

2.  rpoB mutation conferring rifampin resistance in Streptococcus pyogenes.

Authors:  Hélène Aubry-Damon; Marc Galimand; Guy Gerbaud; Patrice Courvalin
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

3.  Rifampin and rifabutin resistance mechanism in Helicobacter pylori.

Authors:  M Heep; D Beck; E Bayerdörffer; N Lehn
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

4.  rpoB mutations in Streptococcus mitis clinical isolates resistant to rifampin.

Authors:  Wafa Achour; Olfa Guenni; Marguerite Fines; Roland Leclercq; Assia Ben Hassen
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

5.  New species genetic approach to identify strains of mitis group streptococci that are donors of rifampin resistance to Streptococcus pneumoniae.

Authors:  María-José Ferrándiz; Carmen Ardanuy; Josefina Liñares; Luz Balsalobre; María Teresa García; Adela G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2010-11-01       Impact factor: 5.191

6.  Barriers to genetic exchange between bacterial species: Streptococcus pneumoniae transformation.

Authors:  J Majewski; P Zawadzki; P Pickerill; F M Cohan; C G Dowson
Journal:  J Bacteriol       Date:  2000-02       Impact factor: 3.490

7.  Molecular basis of rifampin resistance in Streptococcus pneumoniae.

Authors:  T Padayachee; K P Klugman
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

8.  Hyperrecombination in Streptococcus pneumoniae depends on an atypical mutY homologue.

Authors:  M M Samrakandi; F Pasta
Journal:  J Bacteriol       Date:  2000-06       Impact factor: 3.490

9.  Frequency, spectrum, and nonzero fitness costs of resistance to myxopyronin in Staphylococcus aureus.

Authors:  Aashish Srivastava; David Degen; Yon W Ebright; Richard H Ebright
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

10.  Antibiotic susceptibilities of Anaplasma (Ehrlichia) phagocytophilum strains from various geographic areas in the United States.

Authors:  Max Maurin; Johan S Bakken; J Stephen Dumler
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.